The Effect of 3-Month Growth Hormone Administration and 12-Month Follow-Up Duration among Heart Failure Patients Four Weeks after Myocardial Infarction: A Randomized Double-Blinded Clinical Trial.

Afshin Amirpour,Behzad Yavari,Reihaneh Zavar,Mehrbod Vakhshoori,Masoumeh Sadeghi,Hadi Zarei,Brian Tomlinson

doi:10.1155/2021/2680107

Afshin Amirpour, Behzad Yavari + Show 5 more

Open Access

https://doi.org/10.1155/2021/2680107

Copy DOI

Abstract

Background The probable impact of growth hormone (GH) as a heart failure (HF) treatment strategy is still less investigated. Therefore, we aimed to evaluate the relation of 3-month GH prescription on left ventricular ejection fraction (LVEF), interventricular septum (IVS), posterior left ventricle (LV) thickness, end systolic and end diastolic diameters (ESD and EDD), and pulmonary arterial pressure (PAP) among Iranian individuals suffering from HF due to MI attack. Methods A total of 16 clinically stable participants with HF diagnosis and LVEF < 40% were selected for enrollment in this pilot randomized double-blinded study. They were randomly assigned equally to groups received 5 IU subcutaneous GH or placebo. Injections were done every other day for a total of 3-month duration. After termination of intervention and nine months afterwards, cardiac outcomes were assessed. Results Baseline and 12-month posttrial participants' characteristics were similar. LVEF was increased significantly by three months started from baseline in individuals receiving GH (32 ± 3.80% to 43.80 ± 4.60%, P = 0.002). During the next 9 months of follow-up concurrent with cessation of injections, LVEF was declined (43.80 ± 4.60% to 32.20 ± 6.97%, P = 0.008). LVEF and ESD were remarkably higher and lower in GH group compared with controls by the end date of injections (43.80 ± 4.60% vs. 33.14 ± 4.84%, P = 0.02 and 39.43 ± 3.45 mm vs. 33 ± 3.16 mm, P = 0.03, respectively). No other considerable association was found in terms of other predefined variables in neither GH nor placebo groups. Conclusions GH administration in HF patients was associated with increased LVEF function. Several randomized clinical trials are necessary proving this relation. This trial is registered with IRCT201704083035N1.

Highlights

The probable impact of growth hormone (GH) as a heart failure (HF) treatment strategy is still less investigated
Any healthy male patients with no prior positive cardiac history aged as low as 40 to as high as 70 years with his first experience of myocardial infarction (MI) due to single vessel left anterior descending (LAD) involvement with just one active plaque which had been fully revascularized afterwards leading to decreasing ejection fraction (EF) to less than 40% confirmed by two distinct echocardiography physicians at the time of discharge was eligible for being recruited in our study
The current study is aimed at evaluating the relation between GH administration and clinical cardiovascular outcomes in Iranian HF patients due to LAD infarction with one active plaque

Summary

Introduction

The probable impact of growth hormone (GH) as a heart failure (HF) treatment strategy is still less investigated. A total of 16 clinically stable participants with HF diagnosis and LVEF < 40% were selected for enrollment in this pilot randomized doubleblinded study. They were randomly assigned to groups received 5 IU subcutaneous GH or placebo. LVEF was increased significantly by three months started from baseline in individuals receiving GH (32 ± 3:80% to 43:80 ± 4:60%, P = 0:002). GH administration in HF patients was associated with increased LVEF function. Six months of GH treatment in 22 CHF individuals due to ischemia did not demonstrate any significant improvements in any LV functional components [15]

Objectives

Methods

Results

Conclusion